|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2009-9-2
|
|
pubmed:abstractText |
EphA2 is overexpressed in many types of human cancer but is absent or expressed at low levels in normal epithelial tissues. We investigated whether a novel immunoconjugate containing an anti-EphA2 monoclonal antibody (1C1) linked to a chemotherapeutic agent (monomethyl auristatin phenylalanine [MMAF]) through a noncleavable linker maleimidocaproyl (mc) had antitumor activity against ovarian cancer cell lines and tumor models.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD31,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates,
http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Proliferating Cell Nuclear Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, EphA2,
http://linkedlifedata.com/resource/pubmed/chemical/monomethyl auristatin E
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
pubmed-author:ColemanRobert LRL,
pubmed-author:FazenbakerChristineC,
pubmed-author:GooyaJohnJ,
pubmed-author:HanHee DongHD,
pubmed-author:JacksonDowdyD,
pubmed-author:KimHye-SunHS,
pubmed-author:KimSeung WookSW,
pubmed-author:LandenCharles NCN,
pubmed-author:LangleyRobert RRR,
pubmed-author:LeeJeong-WonJW,
pubmed-author:LuChunhuaC,
pubmed-author:MangalaLingegowda SLS,
pubmed-author:MaoShenlanS,
pubmed-author:NickAlpa MAM,
pubmed-author:SchmandtRosemarieR,
pubmed-author:ShahzadMian M KMM,
pubmed-author:SoodAnil KAK,
pubmed-author:TiceDavid ADA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
2
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1193-205
|
|
pubmed:dateRevised |
2011-8-1
|
|
pubmed:meshHeading |
pubmed-meshheading:19641174-Animals,
pubmed-meshheading:19641174-Antibodies, Monoclonal,
pubmed-meshheading:19641174-Antigens, CD31,
pubmed-meshheading:19641174-Antineoplastic Agents,
pubmed-meshheading:19641174-Apoptosis,
pubmed-meshheading:19641174-Blotting, Western,
pubmed-meshheading:19641174-Cell Line, Tumor,
pubmed-meshheading:19641174-Cell Survival,
pubmed-meshheading:19641174-Female,
pubmed-meshheading:19641174-Fluorescent Antibody Technique,
pubmed-meshheading:19641174-Humans,
pubmed-meshheading:19641174-Immunoconjugates,
pubmed-meshheading:19641174-Immunohistochemistry,
pubmed-meshheading:19641174-In Situ Nick-End Labeling,
pubmed-meshheading:19641174-Mice,
pubmed-meshheading:19641174-Oligopeptides,
pubmed-meshheading:19641174-Ovarian Neoplasms,
pubmed-meshheading:19641174-Proliferating Cell Nuclear Antigen,
pubmed-meshheading:19641174-Receptor, EphA2,
pubmed-meshheading:19641174-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
|
|
pubmed:affiliation |
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
